AAV Gene Therapy for TK2 Deficiency in Mitochondrial DNA Depletion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There are no proven effective treatments or cures for mitochondrial diseases, particularly mitochondrial DNA depletion syndromes, which are often fatal in childhood or early adult life, due to defects in mitochondrial respiratory chain enzymes and unbalanced nucleotide pools.
Innovation Solution
Administering compositions containing transgenes encoding proteins such as TK2, dGK, TP, p53R2, SUCLA2, SUCLG1, MPV17, and/or POLG using viral vectors like AAV to restore enzyme activity and balance nucleotide pools, thereby treating, preventing, or curing mitochondrial diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If gene therapy compositions are administered to restore enzyme activity, then treatment effectiveness is improved, but delivery efficiency and targeting precision remain insufficient
Solution Approach 1:
The patent uses adeno-associated virus (AAV) vectors as intermediary carriers to deliver gene therapy compositions. The AAV vector serves as a mediator between the therapeutic gene and target cells, enabling efficient transduction and sustained expression of enzymes like TK2, dGK, TP, p53R2, SUCLA2, SUCLG1, MPV17, and POLG. This intermediary approach resolves the contradiction by providing a reliable delivery mechanism that overcomes the complexity of direct gene administration.
2Adaptability or versatility
If multiple enzyme deficiencies are addressed simultaneously, then comprehensive treatment is improved, but therapeutic target precision becomes difficult to achieve
Solution Approach 1:
The patent addresses multiple enzyme deficiencies by segmenting the therapeutic approach into separate gene therapy compositions, each targeting a specific enzyme (TK2, dGK, TP, p53R2, SUCLA2, SUCLG1, MPV17, or POLG). This segmentation allows for precise targeting of individual enzyme deficiencies while maintaining the ability to treat comprehensive cases by selecting appropriate combinations. Each segmented therapy can be independently optimized and delivered to achieve both versatility and precision.
3Reliability
If mitochondrial DNA depletion syndromes are treated, then patient survival is improved, but nucleotide pool balance remains unbalanced
Solution Approach 1:
The patent employs feedback mechanisms where the restored enzymes (TK2, dGK, TP, p53R2, etc.) continuously monitor and regulate nucleotide pool composition. These enzymes catalyze reactions that convert substrates into nucleotides, and their activity levels automatically adjust to maintain balanced nucleotide pools. The feedback loop ensures that as nucleotide levels change, enzyme activity相应ly adjusts to restore and maintain balance, thereby improving patient survival while simultaneously correcting nucleotide pool imbalance.
Data Source
AI summary
The invention relates generally to a method of treatment for a human genetic disease, such as diseases characterized by unbalanced nucleotide pools, e.g., mitochondrial DNA depletion syndromes, and more specifically, thymidine kinase 2 (TK2) deficiency, using gene therapy. The gene therapy may involve administration of one or more constructs, such as a viral vector, containing a nucleic acid encoding a functional protein. The functional protein may correspond to a nuclear gene. For treatment of TK2 deficiency, the gene therapy may involve administration of one or more constructs, such as a viral vector, containing a nucleic acid encoding a functional TK2 enzyme. The treatment may also involve the administration of pharmacological therapy in conjunction with the gene therapy. The treatment protocols of the disclosure, such as those involving gene therapy alone or in combination with pharmacological therapy, can be used to treat, prevent, and/or cure various other disorders of unbalanced nucleoside pools, especially those found in mitochondrial DNA depletion syndrome.